Abstract
Data on the benefits of cardiac resynchronization therapy (CRT) in patients with severe heart failure (HF) symptoms are limited. We investigated the relative effects of CRT in patients with ambulatory NYHA IV vs. III functional class at the time of device implantation. In this meta-analysis, we pooled patient-level data from the MIRACLE, MIRACLE-ICD, and COMPANION trials. Outcomes evaluated were time to the composite endpoint of first HF hospitalization (HFH) or all-cause mortality and time to all-cause mortality alone. The association between CRT and outcomes was evaluated using a Bayesian Hierarchical Weibull survival regression model. We assessed if this association differs between NYHA III and IV groups by adding an interaction term between CRT and NYHA class as a random effect. A sensitivity analysis was performed by including data from the RAFT trial. Our pooled analysis included 2309 patients. Overall, CRT was associated with a longer time to HFH or all-cause mortality (adjusted hazard ratio [aHR] 0.79, 95%CI 0.64 – 0.99, p = 0.044), with a similar association with time to all-cause mortality (aHR 0.78, 95% CI 0.59 – 1.03, p = 0.083). Associations of CRT with outcomes were not significantly different for those in NYHA III and IV classes (ratio of aHR 0.72, 95% CI 0.30 – 1.27, p = 0.23 for HFH/mortality; ratio of aHR 0.70, 95% CI 0.35 – 1.34, p = 0.27 for all-cause mortality alone). The sensitivity analysis, including RAFT data, did not show a significant relative CRT benefit between NYHA III and IV classes. Overall, there was no significant difference in the association of CRT with either outcome for patients in NYHA functional class III compared with functional class IV.
Competing Interest Statement
1.Friedman: Received research grants from the Abbott, American Heart Association, Biosense Webster, Boston Scientific, Medtronic, Merit Medical, National Cardiovascular Data Registry, Phillips, and National Institutes of Health; received consulting fees from Abbott, NI Medical, Microport, and Sanofi. 2.Fudim: On the Speaker Board for Medtronic, Abbott, Boston Scientific 3.Curtis: On Advisory board of Abbott, Janssen Pharmaceuticals, Milestone Pharmaceuticals, Medtronic, Eagle Pharmaceuticals; honoraria for speaking for Abbott, Medtronic, Sanofi Aventis 4.Gold: Research grants and consulting fees from Boston Scientific and Medtronic; Steering Committee with Boston Scientific, EBR and Medtronic 5.Al-Khatib: Received modest research grants from Medtronic and Boston Scientific paid to her institution that have ended. 6.Cleland: Supported by a British Heart Foundation Centre of Research Excellence (grant number RE/18/6/34217); Reports grants from British Heart Foundation, personal fees from Abbott, personal fees from Amgen, grants and personal fees from Bayer, grants and personal fees from Bristol Myers Squibb, personal fees from Novartis, personal fees from Medtronic, personal fees from Idorsia, grants and personal fees from Pharmacosmos. grants and personal fees from Vifor, personal fees from Servier, personal fees and non-financial support from Boehringer-Ingelheim, personal fees from Astra-Zeneca, personal fees from Biopeutics, personal fees from Moderna, grants and personal fees from Viscardia, personal fees and non-financial support from NI Medical, grants from Pharma Nord.
Clinical Trial
This was a meta-analysis and thus did not require a trial ID in a trial registry.
Funding Statement
Primary funding was provided by the National Heart, Lung, and Blood Institute (1R01HL131754). NHLBI did not participate in the literature search, determination of study eligibility criteria, data analysis or interpretation, or preparation or approval of the manuscript for publication.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
We have IRB approval from Duke to conduct all the analyses. The original trials were all IRB approved and all patients had to provide informed consent.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
We are not able to make our data available as we have contractual agreements with the PIs and/or sponsors of the trials that do not allow us to share the data.
